MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes

Rhea-AI Summary

MiniMed (Nasdaq: MMED) launched in Europe the MiniMed™ 780G system integrated with the 15-day Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor, both made by Abbott.

CE-marked Instinct sensors expand MiniMed's portfolio, offering smaller, longer-wear CGM options with clinical data showing high Time in Range and strong overnight control.

Positive

• Commercial launch of Instinct and Instinct Go sensors across European markets
• MiniMed™ 780G system now compatible with 15-day Instinct sensor
• CE mark approval obtained for Instinct sensors integration with MiniMed systems
• Real-world data show many MiniMed™ 780G users reach 80% Time in Range
• Study of 8,019 users reports 91% overnight Time in Range with MiniMed™ 780G
• Randomized crossover study shows similar glycemic outcomes with Instinct and Simplera Sync™ sensors

Negative

• None.

News Market Reaction – MMED

-3.38%

19 alerts

-3.38% Session close to close

+4.8% Peak in 1 hr 7 min

$4.21B Market Cap

0.2x Rel. Volume

In the Jun 23 session, MMED declined 3.38%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands MiniMed’s European sensor options, pairing Instinct with MiniMed 780G and ...

Analysis

This announcement expands MiniMed’s European sensor options, pairing Instinct with MiniMed 780G and Go systems and supported by outcomes from over 20,000 users. Investors may watch adoption trends and how this supports progress toward profitability.

Key Figures

Pre-meal bolus window: 15–20 minutes Sensor wear duration: 15 days Real-world users: Over 20,000 users +5 more

8 metrics

Pre-meal bolus window 15–20 minutes Recommended timing before meals to help control post-meal glucose

Sensor wear duration 15 days Instinct sensor wear time in MiniMed 780G integration

Real-world users Over 20,000 users U.S. MiniMed 780G real-world analysis sample size

Guideline Time in Range 70% TIR ADA and international consensus guideline benchmark

Achieved Time in Range 80% TIR Many MiniMed 780G users with optimal settings

Overnight Time in Range 91% TIR Overnight TIR in 8,019 U.S. MiniMed 780G users

Real-world cohort size 8,019 users U.S. MiniMed 780G overnight Time in Range analysis

Optimal AIT setting 2 hours Active Insulin Time used >95% of the time for optimal results

Historical Context

5 past events · Latest: Jun 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 17	Product launch	Positive	-3.6%	U.S. launch of MiniMed Flex pump paired with Simplera Sync sensor.
Jun 03	Sensor partnership	Positive	+15.9%	Expanded Abbott agreement for dual glucose-ketone sensors for MiniMed systems.
Jun 03	Earnings results	Positive	+15.9%	Strong Q4 and FY26 revenue growth with FY27 outlook and margin targets.
May 27	Conference showcase	Positive	-3.4%	Showcase of MiniMed Flex and MiniMed Go at ADA Scientific Sessions.
May 26	Investor conference	Neutral	-5.8%	Participation in Goldman Sachs Global Healthcare Conference fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent MMED news often shows mixed price reactions, with several positive product updates met by negative or muted moves.

Key Terms

randomized crossover study, real-world analysis, time in range (tir), ce mark approval, +1 more

5 terms

randomized crossover study medical

"Recent data from a new randomized crossover study, published in Diabetes Technology & Therapeutics..."

A randomized crossover study is a clinical trial design where participants are randomly assigned to receive two or more treatments in different sequences, so each person acts as their own comparison over time—like trying two recipes in random order to judge which tastes better. For investors, it matters because this design can give clearer, more efficient comparisons of effectiveness or safety with fewer subjects, but results can be affected if one treatment's effects carry over into the next period.

real-world analysis medical

"These results were reinforced by a real-world analysis of over 20,000 U.S. users..."

Real-world analysis examines how a product, treatment, or service performs in everyday settings using data from routine practice, sales, claims, devices, or customer behavior rather than controlled tests or lab studies. For investors it provides a clearer picture of market acceptance, costs, safety and long-term performance—think of it as watching a car on public roads instead of only on a test track, revealing how well something actually works and sells when people use it in real life.

time in range (tir) medical

"guidelines of 70% Time in Range (TIR), with many users achieving 80% TIR..."

The percentage of time a person’s blood sugar stays within a pre-set target range, usually measured by a continuous glucose monitor; think of it as a fuel gauge showing how often levels stay in the “green” zone. Investors care because higher time in range is a simple, widely accepted measure of a device or therapy’s effectiveness, and it can influence regulatory decisions, insurance coverage, patient adoption and long-term demand for related products.

ce mark approval regulatory

"begin rolling out across European markets this month following CE mark approval earlier this year..."

CE mark approval is a declaration that a product meets European safety, health and performance requirements and may be placed on the market in the European Economic Area; for regulated items such as medical devices this follows required testing or a conformity assessment. Think of it as a passport or safety sticker that opens access to European customers; for investors it reduces regulatory roadblocks and can materially expand addressable market and revenue potential, though it is not a guarantee of commercial success.

continuous glucose monitoring (cgm) medical

"real-time CGM data, addressing the therapy adherence gap for MDI users..."

A continuous glucose monitoring (CGM) system is a small wearable sensor and transmitter that measures a person’s blood sugar levels continuously and sends real‑time readings to a display or smartphone app, reducing the need for finger‑prick tests. Investors care because CGM shifts diabetes care toward ongoing device sales, subscriptions and data services; wider patient adoption, insurance coverage and better accuracy can drive steady revenue and create opportunities for new health products and analytics, similar to moving from one‑off purchases to a subscription service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company's portfolio

NORTHRIDGE, Calif., June 23, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMed™ 780G system integrated with the Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor. The Instinct and Instinct Go sensors, made by Abbott, will be rolled out gradually across Europe starting this month, expanding MiniMed's sensor portfolio in the region. 

"People with diabetes should not have to choose between flexibility and performance when managing their diabetes — and with MiniMed, they don't have to," said Que Dallara, CEO, MiniMed. "Expanding our sensor portfolio across Europe with Instinct and Instinct Go means more people can access the proven outcomes, intelligent insights, and seamless automation MiniMed is known for. This is about meeting people where they are and building technology that fits their life — not the other way around. That's what drives us every day."

For people with type 1 diabetes, accurately counting carbs and remembering to take insulin up to 15 minutes before meals can be challenging, often leading to post-meal blood glucose spikes when doses are delayed, missed, or underestimated.

The MiniMed™ 780G system is the only system with Meal Detection™ technology* designed to reduce post-meal blood glucose spikes when users occasionally forget to bolus or underestimate carbs. Paired with the 15-day Instinct sensor—the world's smallest, thinnest, and most discreet sensor with demonstrated strong glucose accuracy^1,2—the MiniMed™ 780G system offers greater choice and flexibility while maintaining proven clinical performance. Recent data from a new randomized crossover study, published in Diabetes Technology & Therapeutics, demonstrated glycemic outcomes were virtually identical when using the MiniMed™ 780G system with either the Simplera Sync™ sensor or Instinct sensor. These results were reinforced by a real-world analysis of over 20,000 U.S. users of the MiniMed 780G system, validating the algorithm's central role in driving results.^6,7

Clinical and real-world evidence suggest that the MiniMed™ 780G system can help people with type 1 diabetes achieve consistent glycemic control that substantially exceeds ADA and international consensus guidelines of 70% Time in Range (TIR), with many users achieving 80% TIR^{3,4  ∞} when using optimal settings. A separate real-world study of 8,019 U.S. MiniMed™ 780G system users (aged 7 years or older) demonstrated that the system delivered 91% overnight Time in Range⁵ **^{^ ∞} which means fewer beeps, fewer alarms and a restful sleep.

For people using multiple daily injections (MDI), diabetes management remains fragmented across disconnected tools, creating constant "mental math" in daily life. The MiniMed Go™ system integrated with the Instinct Go sensor brings it all together in one place. It is the first solution to combine dose tracking with the InPen™ smart insulin pen and real-time CGM data, addressing the therapy adherence gap for MDI users by providing real-time alerts and actionable insights on a single mobile app when doses are missed or blood glucose spikes – helping MDI users stay on top of their diabetes with less effort.

"People with diabetes have different preferences, lifestyles, and needs, which is why choice matters," said Professor Amir Tirosh of Sheba Medical Center and Tel-Aviv University. "The integration of the Instinct sensor with the MiniMed™ 780G and MiniMed Go™ systems allows more people to access advanced diabetes technology in a way that works for them, while still benefiting from the proven algorithm and clinical outcomes that have made these systems so impactful."

The Instinct and Instinct Go sensors begin rolling out across European markets this month following CE mark approval earlier this year for integration with the two systems.

Frequently Asked Questions
Q: What is the MiniMed™ 780G system?
A: It's MiniMed's most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows and making diabetes management easier and less time-consuming.^§

Q: What is the MiniMed Go™ system?
A: The MiniMed Go™ system is a smart diabetes management solution that connects the InPen™ smart insulin pen with either the Simplera™ sensor or Instinct Go sensor, made by Abbott, through the single MiniMed Go™ app. It provides real-time glucose data, dose calculations, missed dose alerts, and actionable guidance, making MDI therapy easier and more connected.

Q: What makes the Instinct sensor different?
A: The Instinct sensor, made by Abbott, is easy to use and comfortable to wear⁸ for up to 15 days. It's the world's smallest^1,2, thinnest¹ and most discreet² sensor and is designed to work exclusively with MiniMed smart dosing systems.

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
** Overnight period: 12:00 AM- 6:00 AM [24:00 h–06:00 h]. CareLink™ data including CGM metrics, alarms/alerts, and insulin delivery were evaluated in 8019 US MiniMed™ 780G system users (aged ≥7 years, as of 6 November 2023) who transitioned from the MiniMed™ 770G system and had ≥14 nights of CGM data on both systems. CareLink™ data were analysed between 26 February 2023, and 21 October 2023, for MiniMed™ 770G users, and between 8 August 2023, and 6 November 2023, for MiniMed™ 780G users.
^§ Refers to SmartGuard™ feature. Individual results may vary
^ Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
∞ Reached using optimal settings, Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time. SmartGuard™ feature settings for each single patient must be defined by HCPs based on individual targets and specific needs

The sensor shape and appearance, Abbott, and "a" logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image © 2026 Abbott. ™* Third–party brands are trademarks of their respective owners.

1. Among patient-applied sensors.
2. Data on file. Abbott Diabetes Care, Inc.
3. Thrasher JR, Arrieta A, Niu F, Cameron KR, Cordero TL, Shin J, Rhinehart AS, Vigersky RA. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Diabetes Technol Ther. 2024 Mar;26(S3):24-31. doi: 10.1089/dia.2023.0453. PMID: 38377317
4. Choudhary P, Arrieta A, van den Heuvel T, Castañeda J, Smaniotto V, Cohen O. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. 2024 Mar;26(S3):32-37. doi: 10.1089/dia.2023.0433. PMID: 38377326; PMCID: PMC10890936.
5. McVean, et al. . Diabetes Obes Metab. 2026;28(3):2456-2460
6. Laron-Hirsch, M., et al. Glycemic concordance of Simplera Sync™ and Instinct sensors in MiniMed™ 780G system users: A randomized crossover feasibility study. Diabetes Technology and Therapeutics. DOI:10.1177/15209156261449884
7. Data on file.
8. Alva, Shridhara, Ronald Brazg, Kristin Castorino, Mark Kipnes, David R. Liljenquist, and Hanqing Liu. "Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System." Diabetes Therapy 14, no. 4 (2023): 767-776. https://doi.org/10.1007/s13300-023-01385-6.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-launches-instinct-sensors-in-europe-giving-people-with-diabetes-more-sensor-choice-with-the-same-proven-outcomes-302806652.html

SOURCE MiniMed

FAQ

What did MiniMed (MMED) announce on June 23, 2026 about Instinct sensors in Europe?

MiniMed announced the European commercial launch of Instinct and Instinct Go sensors integrated with the MiniMed™ 780G and MiniMed Go™ systems. According to MiniMed, rollout across European markets begins this month, following earlier CE mark approval for integration with these diabetes management systems.

How do Instinct sensors work with the MiniMed™ 780G system for MMED investors?

Instinct sensors provide real-time glucose data to the MiniMed™ 780G system, which automatically adjusts insulin every five minutes. According to MiniMed, this combination aims to reduce highs and lows and can help many users exceed 70% Time in Range when using optimal settings.

What clinical outcomes are reported for the MiniMed™ 780G system with Instinct for MMED?

Clinical and real-world data suggest MiniMed™ 780G users can often achieve around 80% Time in Range with optimal settings. According to MiniMed, a separate 8,019-user study showed 91% overnight Time in Range, indicating strong nighttime glucose control in everyday use.

What is the MiniMed Go™ system with Instinct Go sensor and how does it help MDI users?

MiniMed Go™ connects the InPen™ smart insulin pen with Simplera™ or Instinct Go sensors in a single app. According to MiniMed, it offers real-time CGM data, dose tracking, missed dose alerts, and guidance, aiming to reduce therapy gaps for multiple daily injection users.

What makes the Instinct sensor launched by MiniMed (MMED) in Europe distinctive?

The Instinct sensor is described as the world's smallest, thinnest and most discreet 15-day CGM in MiniMed’s portfolio. According to MiniMed, it is designed for comfort, ease of use, strong glucose accuracy, and exclusive integration with its smart dosing systems.

Did studies compare Instinct sensors to other CGMs in MiniMed™ 780G users?

A randomized crossover study found virtually identical glycemic outcomes using MiniMed™ 780G with either the Simplera Sync™ sensor or the Instinct sensor. According to MiniMed, this supports the central role of the 780G algorithm rather than the specific compatible sensor used.